Antibe Therapeutics Inc.
ATBPF
$0.2156
$0.025613.47%
| Weiss Ratings | ATBPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | ATBPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ATBPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.16 | |||
| Price History | ATBPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | 0.00% | |||
| 90-Day Total Return | 0.00% | |||
| Year to Date Total Return | 0.00% | |||
| 1-Year Total Return | 11.02% | |||
| 2-Year Total Return | -50.92% | |||
| 3-Year Total Return | -65.34% | |||
| 5-Year Total Return | -94.87% | |||
| 52-Week High % Change | -12.07% | |||
| 52-Week Low % Change | 43.73% | |||
| Price | ATBPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.25 | |||
| 52-Week Low Price | $0.15 | |||
| 52-Week Low Price (Date) | Apr 03, 2024 | |||
| 52-Week High Price (Date) | Apr 08, 2024 | |||
| Valuation | ATBPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | -- | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.26 | |||
| Earnings Per Share Growth | -16.43% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.58 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.22 | |||
| Enterprise Value/EBITDA (TTM) | 2.59 | |||
| Enterprise Value/EBIT | 0.46 | |||
| Market Cap Category | -- | |||
| Dividends and Shares | ATBPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 52.65M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ATBPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 416-922-3460 | |||
| Address | 15 Prince Arthur Avenue Toronto, ON M5R 1B2 | |||
| Website | www.antibethera.com | |||
| Country | Canada | |||
| Year Founded | 2009 | |||
| Profitability | ATBPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ATBPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -19.00% | |||
| Return on Equity | -- | |||
| Income Statement | ATBPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -2.63M | |||
| EBIT (TTM) | -14.76M | |||
| Net Income (TTM) | -13.76M | |||
| Net Income Avl. to Common (TTM) | -13.76M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 0.04% | |||
| EPS Diluted (TTM) | -0.26 | |||
| EPS Diluted Growth (Q YOY) | 3.29% | |||
| Balance Sheet | ATBPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 18.86M | |||
| Cash Per Share (Q) | $0.36 | |||
| Total Current Assets (Q) | 21.27M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 19.64M | |||
| Current Ratio (Q) | 10.055 | |||
| Book Value Per Share (Q) | $0.37 | |||
| Total Assets (Q) | 42.68M | |||
| Total Current Liabilities (Q) | 2.12M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 23.04M | |||
| Total Common Equity (Q) | 19.64M | |||
| Cash Flow | ATBPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 13.97M | |||
| Cash from Financing (TTM) | 117.60K | |||
| Net Change in Cash (TTM) | 549.30K | |||
| Levered Free Cash Flow (TTM) | -9.11M | |||
| Cash from Operations (TTM) | -13.54M | |||
